These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 21242747

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Guidelines for treatment with infliximab for Crohn's disease.
    Hommes DW, Oldenburg B, van Bodegraven AA, van Hogezand RA, de Jong DJ, Romberg-Camps MJ, van der Woude J, Dijkstra G, Dutch Initiative on Crohn and Colitis (ICC).
    Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
    [Abstract] [Full Text] [Related]

  • 23. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
    Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P.
    Gut; 2009 Apr; 58(4):492-500. PubMed ID: 18832518
    [Abstract] [Full Text] [Related]

  • 24. Clinical experience with infliximab therapy in 100 patients with Crohn's disease.
    Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA.
    Am J Gastroenterol; 2000 Dec; 95(12):3490-7. PubMed ID: 11151882
    [Abstract] [Full Text] [Related]

  • 25. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P.
    Gastroenterology; 2003 Apr; 124(4):917-24. PubMed ID: 12671888
    [Abstract] [Full Text] [Related]

  • 26. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P, Belgian Group of Infliximab Expanded Access Program in Crohn's Disease.
    Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time.
    Loftus EV.
    Am J Gastroenterol; 2005 Jul; 100(7):1435-8. PubMed ID: 15984960
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
    Lichtenstein GR.
    Am J Gastroenterol; 2005 Jul; 100(7):1433-5. PubMed ID: 15984959
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.
    N Engl J Med; 2003 Feb 13; 348(7):601-8. PubMed ID: 12584368
    [Abstract] [Full Text] [Related]

  • 33. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
    Gheorghe L, Gheorghe C, Badea M, Vădan R, Pârvulescu I, Toader C, Tugui L, Papuc O, Ionescu R, Preda C, Călin I, Diculescu M.
    Rom J Gastroenterol; 2003 Mar 13; 12(1):7-13. PubMed ID: 12673373
    [Abstract] [Full Text] [Related]

  • 34. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S.
    Gastroenterology; 2015 Jun 13; 148(7):1320-9.e3. PubMed ID: 25724455
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Combination therapy with infliximab and immunomodulators: is the glass half empty?
    Deshpande AR, Abreu MT.
    Gastroenterology; 2008 Jun 13; 134(7):2161-3. PubMed ID: 18482585
    [No Abstract] [Full Text] [Related]

  • 37. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
    Lindsay J, Punekar YS, Morris J, Chung-Faye G.
    Aliment Pharmacol Ther; 2008 Jul 13; 28(1):76-87. PubMed ID: 18410558
    [Abstract] [Full Text] [Related]

  • 38. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F.
    Scand J Gastroenterol; 2006 Sep 13; 41(9):1064-72. PubMed ID: 16938720
    [Abstract] [Full Text] [Related]

  • 39. [Top-down versus Step-Up: new strategies in the treatment of Crohn's disease].
    Meier J, Sturm A.
    Z Gastroenterol; 2009 Feb 13; 47(2):240-2. PubMed ID: 19197829
    [No Abstract] [Full Text] [Related]

  • 40. Infliximab treatment for symptomatic Crohn's disease strictures.
    Pelletier AL, Kalisazan B, Wienckiewicz J, Bouarioua N, Soulé JC.
    Aliment Pharmacol Ther; 2009 Feb 01; 29(3):279-85. PubMed ID: 19035967
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.